A Director at Globus Medical is Exercising Options

By Carrie Williams

Today, a Director at Globus Medical, David Davidar, exercised options of Globus Medical for $2.25M.

Following David Davidar’s last GMED Sell transaction on August 10, 2012, the stock climbed by 26.4%.

Based on Globus Medical’s latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $152 million and quarterly net profit of $25.59 million. In comparison, last year the company earned revenue of $136 million and had a net profit of $26.23 million. The company has a one-year high of $41.70 and a one-year low of $23.04. GMED’s market cap is $3.88B and the company has a P/E ratio of 36.63.

Based on 9 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $37.36, reflecting a 4.7% upside.

Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Globus Medical, Inc. is a medical device company, which engages in developing products that promote healing in patients with musculoskeletal disorders. It classifies products into Innovative Fusion and Disruptive Technology. It operates through the United States and International geographical segments. The company was founded by David C.